N
TNDM icon

Natixis’s Tandem Diabetes Care TNDM Stock Holding History

Natixis’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,500
Closed -$105K – 1364
2026
Q1 		$105K Buy
+5,500
New +$120K ﹤0.01% 944
2025
Q3 		– Sell
-12,200
Closed -$227K – 1224
2025
Q2 		$227K Buy
+12,200
New +$242K ﹤0.01% 784
2024
Q4 		– Sell
-12,200
Closed -$517K – 1188
2024
Q3 		$517K Buy
+12,200
New +$517K ﹤0.01% 633
2023
Q2 		– Sell
-18,151
Closed -$737K – 1151
2023
Q1 		$737K Sell
18,151
-542
-3% -$22.4K 0.01% 567
2022
Q4 		$840K Sell
18,693
-672
-3% -$30.4K ﹤0.01% 660
2022
Q3 		$968K Sell
19,365
-854
-4% -$46.8K ﹤0.01% 772
2022
Q2 		$1.2M Buy
+20,219
New +$1.66M ﹤0.01% 783

Other funds holding TNDM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Natixis's TNDM Position: Q2 2026 in Review

Natixis sold out of Tandem Diabetes Care (TNDM) in Q2 2026, closing a stake of 5,500 shares — an estimated $105K sold.

Natixis first reported a position in TNDM in Q2 2022 and held it in 7 quarters. The position peaked at $1.2M in Q2 2022. 274 funds tracked by Wall St. Rank hold TNDM as of Q2 2026.

  • Natixis reported no remaining Tandem Diabetes Care position as of Q2 2026 after selling out during the quarter.
  • Natixis sold 5,500 Tandem Diabetes Care shares in Q2 2026, an estimated $105K.
  • Natixis first reported a position in Tandem Diabetes Care in Q2 2022 and held it in 7 quarters.
  • Natixis's Tandem Diabetes Care position peaked at $1.2M in Q2 2022.
  • 274 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.